Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Group 1 - Novavax, Inc. will report its fourth quarter and full year 2025 financial results on February 26, 2026, at 8:30 a.m. ET [1] - The conference call will include details on how to join and will be available for replay from February 26, 2026, until March 5, 2026 [1] - Novavax focuses on addressing global health challenges through its vaccine technology, including the Matrix-M® adjuvant and protein-based nanoparticles [1] Group 2 - The company aims to maximize the impact of its technology by forming strategic partnerships for its Matrix-M adjuvant and R&D assets [1] - Contact information for investor relations and media inquiries is provided, indicating the company's commitment to communication with stakeholders [1]